Abstract:Peptides are ideally suited to mimic natural ligands and thereby function in an antagonistic or agonistic way. Furthermore they are able to physiologically disrupt functional complexes due to their small size and specific binding properties. Proteins form homo- or heteromeric (macro)molecular complexes and intricate networks by interacting with small molecules, peptides, nucleic acids or other proteins. On average, five interaction partners have been estimated for any given cellular protein, illustrating the complexity of the formed 'interactomes' and the impact of their investigation. Many protein-protein interactions are mediated by hot-spots, which comprise only a small part of the large binding interface but account for 80% of the binding energy. Thus, these hot spots provide an 'Achilles heel' for pharmaceutical interventions aiming at the disruption of functional protein-protein complexes. Methods to select peptides for defined target structures include display technologies on phages, ribosomes or yeast, and the yeast-two-hybrid system. Once selected, these peptides can be optimized for their binding affinity using peptide arrays. Stabilization of biologically unstable peptides is achieved by the introduction of non-natural amino acids to form so-called peptidomimetics that are resistant to cellular proteases. Moreover, lipocalins and peptide aptamers represent scaffolded binding structures with unique binding characteristics and enhanced stability. In case of extracellular targets, like cell surface receptors or pathogens in patients` plasma, peptide inhibitors have direct access. Addressing intracellular targets with peptides is more difficult since short hydrophilic peptides generally do not cross plasma membranes on their own. However, intracellular uptake of peptides can be achieved by coupling to carrier systems like liposomes or nanoparticles or upon fusion to a protein transduction domain. Alternatively, peptides may be expressed within cells after transduction with viral vectors in a gene therapy setting. This review will summarize the broad potential of peptides as drugs, with special emphasis on peptides which inhibit protein-protein interactions.

Structural information in therapeutic peptides: Emerging applications in biomedicine

Peptides for therapeutic applications – challenges and chances

The Search for Peptide-Based Therapeutics Using Computational Tools

Therapeutic peptides: current applications and future directions

Advancements in peptide-based therapeutics: Design, synthesis and clinical applications

Review on therapeutic potential of peptides: Advancements in synthesis methods, linear and cyclic peptides, and strategies for overcoming challenges

Therapeutic peptides for coronary artery diseases: in silico methods and current perspectives

Peptides as Targeting Agents and Therapeutics: A Brief Overview

Peptides as drugs: from screening to application

Peptide Aptamers with Biological and Therapeutic Applications

The Medicinal Chemistry of Therapeutic Peptides: Recent Developments in Synthesis and Design Optimizations

In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases

From Natural Sources to Therapeutics

Therapeutic Peptides, Proteins and their Nanostructures for Drug Delivery and Precision Medicine

Peptide therapeutics: Targeting the undruggable space

Therapeutic stapled peptides: Efficacy and molecular targets

Therapeutic peptides for chemotherapy: Trends and challenges for advanced delivery systems

Peptide-based supramolecular hydrogels and their biotherapeutic applications

Peptide-based drug discovery through artificial intelligence: towards an autonomous design of therapeutic peptides

Peptide Drugs: Current Status and it's Applications in the Treatment of Various Diseases

A Global Review on Short Peptides: Frontiers and Perspectives